AUMOLERTINIB: 22 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
22
Total FAERS Reports
2 (9.1%)
Deaths Reported
3
Hospitalizations
22
As Primary/Secondary Suspect
2
Life-Threatening
First Report: 20210415 · Latest Report: 20250105
What Are the Most Common AUMOLERTINIB Side Effects?
#1 Most Reported
Off label use
9 reports (40.9%)
#2 Most Reported
Neoplasm progression
8 reports (36.4%)
#3 Most Reported
White blood cell count decreased
3 reports (13.6%)
All AUMOLERTINIB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 9 | 40.9% | 0 | 0 |
| Neoplasm progression | 8 | 36.4% | 0 | 0 |
Who Reports AUMOLERTINIB Side Effects? Age & Gender Data
Gender: 69.2% female, 30.8% male. Average age: 61.2 years. Most reports from: CN. View detailed demographics →
Is AUMOLERTINIB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2021 | 1 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 0 |
What Is AUMOLERTINIB Used For?
| Indication | Reports |
|---|---|
| Non-small cell lung cancer | 10 |
Official FDA Label for AUMOLERTINIB
Official prescribing information from the FDA-approved drug label.